Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fourth orphan drug designation for the same product, OCU400, is distinct in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Diseases Fourth orphan drug designation for the same product, OCU400, is distinct in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Diseases

Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases

Ocugen got a crucial piece of good news from the FDA. But with the company's lead drug years from approval, OCGN stock remains speculative.

What’s Next For Ocugen After Scoring Orphan Drug Status

Ocugen just doesn't have the qualities that make it attractive to me. Particularly under a buck, OCGN stock is one to avoid.

There Are So Many Stocks to Buy — Ocugen Isn’t One of Them

MALVERN, Pa., Aug.  06, 2020  (GLOBE NEWSWIRE) --  Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that it will host a conference call to discuss its Q2 2020 financial results and provide a business update at 8:30 a.m. on Friday, August 14, 2020.

Ocugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET to Discuss Second Quarter 2020 Financial Results and Provide Business Update

OCGN stock offers risky odds with a limited payoff structure. Stay away from Ocugen except for a speculative play.

Long-Term Investors May Want to Keep Away from Ocugen

Third orphan drug designation for the same product, OCU400, is unique in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Degenerative diseases (IRDs) Third orphan drug designation for the same product, OCU400, is unique in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Degenerative diseases (IRDs)

Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease

MALVERN, Pa., July  21, 2020  (GLOBE NEWSWIRE) --  Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced it will present at the World Orphan Drug Congress USA 2020 Conference, to be held virtually from August 24-27, 2020.

Ocugen to Present at World Orphan Drug Congress USA 2020 Conference

ElectroCore Inc

GrubHub

Royal Caribbean Cruises

SAGE Therapeutics

If you’re looking to hedge some downside, or if you think the market has gone too far to the upside, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify several Top Shorts today.

Top Companies To Short As Nasdaq Looks To Break 10,000

Some investors make a profession by scouring penny stocks like Ocugen. For me, I like sound business over a gamble in OCGN stock.

Ocugen Stock Is a Gamble, Not an Investment Opportunity

Ocugen's ambitions are not gaining traction in an environment where most biotech investors are focusing on Covid-19. Thus, the case for OCGN stock is unusually risky.

This Is No Time to Be Speculating on Ocugen

Agenus

Blink Charging

Gritstone Oncology Inc

MannKind

If there’s one thing that's been made more clear, it’s that the stock market and economy are not reflections of each other. An overbought stock market will eventually turn to the downside, and our deep learning algorithms paired with AI have identified several Top Shorts for today.

Top Stocks To Short As The Nasdaq Breaks Above 10,000

Having a compelling story isn’t enough for OCGN stock

Don’t Make a Blind Investment In Ocugen Stock

MALVERN, Pa., June  03, 2020  (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved eye diseases, today announced the appointment of Dr. Mohamed Genead as chair of the Ocugen, Inc. Retina Scientific Advisory Board, which is comprised of prominent experts who provide strategic advice, clinical and regulatory support, and scientific and industry expertise.

Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board

Breakthrough Modifier Gene Therapy platform continues to advance towards clinic Breakthrough Modifier Gene Therapy platform continues to advance towards clinic

Ocugen to Discontinue Phase 3 oGVHD Trial

Ocugen (OCGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Ocugen (OCGN) a New Strong Buy Stock

Although Ocugen stock has a narrow window for tremendous upside, the broader threats of today make OCGN an extreme gamble.
The post Ocugen Stock Offers Investors a Simple Value Proposition appeared first on InvestorPlace.

Ocugen Stock Offers Investors a Simple Value Proposition

Amendment and Exchange of Series A warrants removes the overhang in capital structure Amendment and Exchange of Series A warrants removes the overhang in capital structure

Ocugen Announces Completion of Warrant Exchange

Denny's

Fluidigm

Rocky Brands

Neuronetics Inc

Bet on these top--ranked stocks with rising P/E to realize outsized gains.

Snap Up These 5 Stocks With Rising P/E

MALVERN, Pa., April  07, 2020  (GLOBE NEWSWIRE) --  Ocugen, Inc.  (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced the appointment of Kirsten Castillo and Prabhavathi Fernandes, Ph.D. to its board of directors.  Additionally, as part of a planned transition, Frank Leo, has resigned from the board.

Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors

Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q4 2019 Results - Earnings Call Transcript

Even in the best of circumstances, OCGN stock was never for the faint of heart. With the coronavirus raging everywhere, I’m not sure for whom Ocugen is appropriate.

Always Risky OCGN Stock Just Got More Treacherous

Data support nuclear hormone receptor gene NR2E3 as genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases and potentially serve as a broad-spectrum therapy Data support nuclear hormone receptor gene NR2E3 as genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases and potentially serve as a broad-spectrum therapy

Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

With this in mind, the best bet is to avoid Ocugen stock. Shares could skyrocket if OCU300 shows positive top-line results.

All Bets Are off for Speculative Long-Shot Ocugen Stock

Ocugen stock has fallen far, and needs positive trial results for its OCU300 treatment to turn things around. For now, it's a high-risk play.

High-Risk Ocugen Needs Good Trial Results to Survive

A pipeline of treatments for underserved eye conditions like oGVHD makes OCGN stock worth considering as part of your biotech holdings.
The post Ocugen Is a Bold Biotech Bet, But the Payoff Could Be Rich appeared first on InvestorPlace.

News for Ocugen, Inc. Stock (OCGN)